Study of enasidenib for low blood counts with IDH2 mutation
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had low red blood cells, white blood cells, or platelets for at least 6 months without a clear cause.
- You have an IDH2 gene mutation (R140 or R172) found in a blood or bone marrow test.
- You are 18 years or older.
- You are able to take care of yourself (able to go about daily activities with little or no help).
- You have not had a bone marrow biopsy showing a blood cancer or other serious blood disorder in the last 6 months.
- You do not have active cancer (excluding skin cancer) that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests a new approach to slow or stop the growth of abnormal blood stem cells in people at high risk for developing blood cancers. It is for older adults with low blood counts and specific genetic changes in their blood cells.
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Hear when a new Clonal Cytopenia of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.